| Action Plan |
Action party |
Timeline |
| Strategy 1: Awareness |
| 1.1 Awareness campaign for the general population |
| 1.1.1 |
Revamp the website of Viral Hepatitis Control Office to provide up-to-date information and to improve user experience |
DH |
Completed |
| 1.1.2 |
Review and update the information of the website of Viral Hepatitis Control Office |
DH |
2023Q2 |
| 1.1.3 |
Define yearly themes of awareness campaign across the territory |
SCVH |
Completed for 2020-22 |
| 1.1.4 |
Establish the yearly theme for 2023 – 2024 |
DH |
2022Q4 |
| 1.1.5 |
Launch enhanced awareness campaign, involving Kwai Tsing District Health Centre |
DH & DHC |
2020Q3 |
| 1.2 Professional training for healthcare workers |
| 1.2.1 |
Conduct professional training programmes with the KAP assessment by phases, starting for obstetricians and midwives and extending to other groups of healthcare workers under the similar framework |
HA, DH & constituent Colleges of Hong Kong Academy of Medicine |
Yearly |
| 1.3 Education targeting at-risk populations, patients and their service providers |
| 1.3.1 |
Develop focused education materials for pregnant women about preventive strategies of perinatal HBV transmission |
DH & HA |
2020Q4 |
| 1.3.2 |
Integrate education on safe injection and safer sex practices for prevention of HBV and HCV infection with HIV prevention programme |
DH |
Ongoing |
| 1.3.3 |
Develop standardised training and education materials on HCV infection for service providers of PWID |
DH, HA & NGOs |
2022Q1 |
| 1.4 Building a supportive environment |
| 1.4.1 |
Enhance service capacity of testing and treatment for HBV and HCV infection |
DH & HA |
Ongoing |
| 1.4.2 |
Evaluate HBV- and HCV-related service in the public sector to provide useful statistics and support the longer term planning and capacity building |
HA |
Ongoing |
| Action Plan |
Action party |
Timeline |
| Strategy 3:Prevention |
| 3.1 Reduce mother-to-child transmission of HBV |
| 3.1.1 Using antivirals to prevent MTCT of HBV |
| 3.1.1.1 |
Establish a policy initiative to provide HBsAg-positive mothers with high viral load with a treatment option to use antivirals |
SCVH |
Completed |
| 3.1.1.2 |
Refer all HBsAg-positive mothers in HA for care of HBV infection |
HA |
2021Q1 |
| 3.1.1.3 |
Start using antivirals to prevent MTCT in selected HA hospitals as pilot |
HA |
2020Q1 |
| 3.1.1.4 |
Start using antivirals to prevent MTCT in all HA birthing hospitals |
HA |
2020Q3 |
| 3.1.1.5 |
Provide professional training to specialists in O&G, public and private, about the use of antivirals to prevent MTCT |
DH & HA |
2021Q2 |
| 3.1.1.6 |
Review the acceptance of using antivirals to prevent MTCT |
DH & HA |
2022Q2 |
| 3.1.2 Post-vaccination serologic testing |
| 3.1.2.1 |
Establish a policy initiative to provide PVST to babies born to HBsAg-positive mothers |
SCVH |
Completed |
| 3.1.2.2 |
Establish the implementation plan and resources implication of PVST |
DH & HA |
2020Q4 |
| 3.1.2.3 |
Provide professional training about PVST programme to obstetricians and paediatricians |
DH & HA |
2021Q3 |
| 3.1.2.4 |
Establish the logistics and workflow of PVST |
DH & HA |
2021Q4 |
| 3.1.2.5 |
Implement PVST programme |
DH & HA |
2022Q1 |
| 3.1.2.6 |
Review the acceptance of PVST programme |
DH & HA |
2023Q2 |
| 3.2 Prevent healthcare-related transmission of HBV and HCV |
| 3.2.1 |
Screen all blood donations in a quality-assured manner |
HA |
Ongoing |
| 3.2.2 |
Provide treatment to people contracted HCV through blood / blood product transfusion |
HA |
Ongoing |
| 3.2.3 |
Conduct regular infection control training, including Standard Precautions and sharps injury or mucosal contact prevention and management |
DH & HA |
Ongoing |
| 3.3 Reduce risk and disease burden in vulnerable populations |
| 3.3.1 |
Intensify condom programming and take harm reduction approach |
DH |
Ongoing |
| Action Plan |
Action party |
Timeline |
| Strategy 4: Treatment |
| 4.1 Enhancement of treatment for HBV infection |
| 4.1.1 |
Augment diagnosis and treatment capacity for HBV infection, in terms of laboratory, equipment, drug and model of care |
HA |
Ongoing |
| 4.1.2 |
Review the service provided by nurse clinics |
HA |
2022Q4 |
| 4.1.3 |
Engage HA hepatologists to explore strategies to enhance service capacity for HBV infection in both public and private settings |
DH & HA |
2021Q2 |
| 4.1.4 |
Engage primary care physicians to support management of HBV infection |
DH & HA |
2021Q4 |
| 4.1.5 |
Develop information resources to facilitate management of HBV infection by primary care physicians |
DH & HA |
2023Q1 |
| 4.1.6 |
Promulgate the information resources to primary care physicians |
DH & HA |
2023Q3 |
| 4.1.7 |
Estimate the service need of ultrasound for HCC surveillance |
DH & HA |
2021Q2 |
| 4.2 Expansion of access to direct-acting antivirals for HCV |
| 4.2.1 |
Establish a policy initiative to deploy DAA in HCV treatment in a stepwise manner |
HA |
Completed |
| 4.2.2 |
Expand DAA treatment for hepatitis C patients with METAVIR fibrosis stages F2 or above |
HA |
Completed |
| 4.2.3 |
Expand DAA treatment for all hepatitis C patients |
HA |
2021Q4 |
| 4.2.4 |
Review the number of patients treated with DAA |
HA |
2023Q1 |
| 4.3 Micro-elimination of HCV infection |
| 4.3.1. Screen and treat patients with end stage renal failure on dialysis |
| 4.3.1.1 |
Establish a policy initiative to provide DAA for HCV treatment in all patients undergoing dialysis |
SCVH |
Completed |
| 4.3.1.2 |
Start using DAA to treat HCV infection in all patients undergoing dialysis |
HA |
2020Q1 |
| 4.3.2. Screen and treat patients co-infected with human immunodeficiency virus |
| 4.3.2.1 |
Establish a policy initiative to provide DAA for HCV treatment in all HIV-positive patients |
SCVH |
Completed |
| 4.3.2.2 |
Start using DAA to treat HCV infection in all patients co-infected with HIV |
DH & HA |
2020Q4 |
| 4.3.2.3 |
Review the number of patients co-infected with HCV and HIV treated with DAA |
DH & HA |
2023Q2 |
| 4.3.2.4 |
Assess the number of re-infection among patients co-infected with HCV and HIV after completion of effective HCV treatment |
DH & HA |
2024Q2 |
| 4.4 Promotion of HCV testing in people who inject drugs |
| 4.4.1 |
Establish a policy initiative to promote HCV testing in PWID, who are attending methadone clinics (MCs) or under the custody of Correctional Services Department, for treatment |
SCVH |
Completed |
| 4.4.2 |
Provide specific educational information about HCV transmission, testing and treatment to PWID |
DH |
2021Q1 |
| 4.4.3 |
Engage professional staff and other workers serving PWID at MCs by promoting the importance of HCV infection |
DH |
2021Q2 |
| 4.4.4 |
Identify testing options and algorithms for HCV testing, including the carrying out of a pilot programme, at MCs |
DH |
2021Q4 |
| 4.4.5 |
Educate and engage staff of Correctional Services Department |
DH & CSD |
2021Q4 |